CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin
Authors
Keywords
-
Journal
iScience
Volume 24, Issue 6, Pages 102664
Publisher
Elsevier BV
Online
2021-05-29
DOI
10.1016/j.isci.2021.102664
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells
- (2021) Laura Rosa Mangiapane et al. GUT
- Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51
- (2021) Gwenola Manic et al. CELL DEATH AND DIFFERENTIATION
- Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
- (2021) Lukas Gorecki et al. Cancers
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells
- (2020) Stella Cascioferro et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- 3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma
- (2020) Stella Cascioferro et al. MOLECULES
- CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells
- (2020) Rebecca F. Rogers et al. CANCER RESEARCH
- Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
- (2020) Patrycja Gralewska et al. Journal of Hematology & Oncology
- The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
- (2020) G. Mauri et al. ANNALS OF ONCOLOGY
- New 1,2,4-Oxadiazole Nortopsentin Derivatives with Cytotoxic Activity
- (2019) Stella Cascioferro et al. Marine Drugs
- Oxymatrine Attenuates Tumor Growth and Deactivates STAT5 Signaling in a Lung Cancer Xenograft Model
- (2019) Young Jung et al. Cancers
- Exploiting DNA repair defects in colorectal cancer
- (2019) Nicole M. Reilly et al. Molecular Oncology
- IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer
- (2019) Carlota Colomer et al. MOLECULAR CELL
- Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death
- (2019) Anne M. van Harten et al. Oncogenesis
- Are 90% of deaths from cancer caused by metastases?
- (2019) Hanna Dillekås et al. Cancer Medicine
- Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant
- (2019) Veronica Veschi et al. ONCOGENE
- Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
- (2018) David S. Hong et al. CLINICAL CANCER RESEARCH
- Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer
- (2018) Kristiaan J. Lenos et al. NATURE CELL BIOLOGY
- Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer
- (2018) Sandeep Kumar et al. BIOMEDICINE & PHARMACOTHERAPY
- CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells
- (2017) Gwenola Manic et al. GUT
- A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer
- (2017) Thomas Wehler et al. LUNG CANCER
- Emerging Cytotoxic Alkaloids in the Battle against Cancer: Overview of Molecular Mechanisms
- (2017) Zeina Habli et al. MOLECULES
- The target landscape of clinical kinase drugs
- (2017) Susan Klaeger et al. SCIENCE
- Targeting the ATR-CHK1 Axis in Cancer Therapy
- (2017) Stuart Rundle et al. Cancers
- Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors
- (2016) Emiliano Calvo et al. ONCOLOGY
- A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer
- (2015) Felix Dietlein et al. CELL
- Synthesis and Antiproliferative Activity of Thiazolyl-bis-pyrrolo[2,3-b]pyridines and Indolyl-thiazolyl-pyrrolo[2,3-c]pyridines, Nortopsentin Analogues
- (2015) Anna Carbone et al. Marine Drugs
- Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- (2015) Giulia Siravegna et al. NATURE MEDICINE
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Targeting Apoptosis Pathways in Cancer and Perspectives with Natural Compounds from Mother Nature
- (2014) F. M. Millimouno et al. Cancer Prevention Research
- CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis
- (2014) Matilde Todaro et al. Cell Stem Cell
- Causes of Genome Instability
- (2013) Andrés Aguilera et al. Annual Review of Genetics
- Roles of Chk1 in cell biology and cancer therapy
- (2013) Youwei Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
- (2013) Constance King et al. INVESTIGATIONAL NEW DRUGS
- Colorectal cancer defeating? Challenge accepted!
- (2013) S. Di Franco et al. MOLECULAR ASPECTS OF MEDICINE
- Causes and consequences of replication stress
- (2013) Michelle K. Zeman et al. NATURE CELL BIOLOGY
- Alkaloids Isolated from Natural Herbs as the Anticancer Agents
- (2012) Jin-Jian Lu et al. Evidence-based Complementary and Alternative Medicine
- Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer
- (2012) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Synthesis and in-vitro anticancer activity of 3,5-bis(indolyl)-1,2,4-thiadiazoles
- (2011) Dalip Kumar et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Wnt activity defines colon cancer stem cells and is regulated by the microenvironment
- (2010) Louis Vermeulen et al. NATURE CELL BIOLOGY
- Correlation of CD133, OCT4, and SOX2 in Rectal Cancer and Their Association with Distant Recurrence After Chemoradiotherapy
- (2009) Susumu Saigusa et al. ANNALS OF SURGICAL ONCOLOGY
- Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity
- (2009) M Walker et al. ONCOGENE
- Natural compounds for cancer treatment and prevention
- (2009) Stefania Nobili et al. PHARMACOLOGICAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More